BEONE BIO
DEAD

Serial Number

98746786

Owner

BeiGene Switzerland GMBH

Attorney

Kristen Ruisi

Filing Date

Sep 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BEONE BIO Trademark

Serial Number: 98746786

BEONE BIO is a trademark filed by BeiGene Switzerland GMBH on September 12, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

BeiGene Switzerland GMBH

Aeschengraben 27
Basel 4051 , CH

Entity Type: 16

Trademark Details

Filing Date

September 12, 2024

Registration Date

Not Registered

Goods & Services

Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advice, namely, pharmaceutical advice

Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; conducting clinical trials for others for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging design

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jul 23, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jul 23, 2025 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 17, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 17, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 17, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 12, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 27, 2025 NWOS
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Sep 16, 2024 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Sep 16, 2024 PARI
NEW APPLICATION ENTERED
Sep 12, 2024 NWAP